Women with these genotypes are at higher risk of developing breast cancer; continuing the exposure to estrogens through therapy might increase the risk, and once these polymorphisms lead to inefficient estrogens detoxification, these estrogens might turn biologically active by binding to ER, contributing to the development of hormone-dependent breast cancer. This evidence concerns the gene ESR1 and breast cancer.